Sackett J F, Strother C M, Quaglieri C E, Javid M J, Levin A B, Duff T A
Radiology. 1977 Jun;123(3):779-82. doi: 10.1148/123.3.779.
Two-hundred-fifteen patients were evaluated with metrizamide, a new water-soluble contrast agent for use in the subarachnoid spaces. Side effects were reported in 67% of these; 39% were moderate or severe. Cervical injections monitored by fluoroscopy provide the most precise positioning of the medium. The benefits of metrizamide use outweigh its risk.
